Replies to post #14598 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

My 3Q15 Glatopa estimates in #msg-116782888 ($104M in-market sales; $41.5M revenue to MNTA) may be too high, based on the recent script data. However, I’m sticking with the above numbers (for now) because the scripts reported by IMS and Symphony can be unreliable for generic drugs.